title: DREAM plays an important role in platelet activation and thrombogenesis.
abstract: Downstream regulatory element antagonist modulator (DREAM), a transcriptional repressor, is known to modulate pain responses. However, it is unknown whether DREAM is expressed in anucleate platelets and plays a role in thrombogenesis. By using intravital microscopy with DREAM-null mice and their bone marrow chimeras, we demonstrated that both hematopoietic and nonhematopoietic cell DREAMs are required for platelet thrombus formation following laser-induced arteriolar injury. In a FeCl3-induced thrombosis model, we found that compared with wild-type (WT) control and nonhematopoietic DREAM knockout (KO) mice, DREAM KO control and hematopoietic DREAM KO mice showed a significant delay in time to occlusion. Tail bleeding time was prolonged in DREAM KO control mice, but not in WT or DREAM bone marrow chimeric mice. In vivo adoptive transfer experiments further indicated the importance of platelet DREAM in thrombogenesis. We found that DREAM deletion does not alter the ultrastructural features of platelets but significantly impairs platelet aggregation and adenosine triphosphate secretion induced by numerous agonists (collagen-related peptide, adenosine 5'-diphosphate, A23187, thrombin, or U46619). Biochemical studies revealed that platelet DREAM positively regulates phosphoinositide 3-kinase (PI3K) activity during platelet activation. Using DREAM-null platelets and PI3K isoform-specific inhibitors, we observed that platelet DREAM is important for α-granule secretion, Ca2+mobilization, and aggregation through PI3K class Iβ (PI3K-Iβ). Genetic and pharmacological studies in human megakaryoblastic MEG-01 cells showed that DREAM is important for A23187-induced Ca2+mobilization and its regulatory function requires Ca2+binding and PI3K-Iβ activation. These results suggest that platelet DREAM regulates PI3K-Iβ activity and plays an important role during thrombus formation.
authors.affiliation: Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL.
authors.forename: Kyungho
authors.initials: K
authors.lastname: Kim
authors.affiliation: Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL.
authors.forename: Alan
authors.initials: A
authors.lastname: Tseng
authors.affiliation: Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL.
authors.forename: Andrew
authors.initials: A
authors.lastname: Barazia
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, MA; and.|Department of Medicine, Harvard Medical School, Boston, MA.
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Italiano
authors.affiliation: Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL.
authors.forename: Jaehyung
authors.initials: J
authors.lastname: Cho
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000378:metabolism; D004195:Disease Models, Animal; D005434:Flow Cytometry; D006801:Humans; D015151:Immunoblotting; D047468:Immunoprecipitation; D051605:Kv Channel-Interacting Proteins / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015539:Platelet Activation / Q000502:physiology*; D016133:Polymerase Chain Reaction; D012097:Repressor Proteins / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D013927:Thrombosis / Q000378:metabolism*
chemical_list: C496756:Csen protein, mouse; D051605:Kv Channel-Interacting Proteins; D012097:Repressor Proteins